Pfizer and BioNTech said Thursday that trials suggest their vaccine is effective against a coronavirus variant that first emerged in South Africa, which some experts worry might evade existing shots. The drugmakers also said in a statement that 12,000 people involved in their Phase 3 trial experienced high levels of protection against Covid-19 six months after their second dose, with no serious safety concerns. |
No comments:
Post a Comment